Salix Pharma (SXLP) Announces Data from Phase 3 Trials of XIFAXAN
Tweet Send to a Friend
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) announced Monday that it has during the Phase 3 clinical trials, IFAXAN 550 mg (rifaximin) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
